Ciba Pharmaceutical Products, Inc. v. Towns & James, Inc.

123 F. Supp. 894, 1954 U.S. Dist. LEXIS 3111, 1954 Trade Cas. (CCH) 67,826
CourtDistrict Court, E.D. New York
DecidedJuly 19, 1954
DocketCiv. No. 14326
StatusPublished

This text of 123 F. Supp. 894 (Ciba Pharmaceutical Products, Inc. v. Towns & James, Inc.) is published on Counsel Stack Legal Research, covering District Court, E.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Ciba Pharmaceutical Products, Inc. v. Towns & James, Inc., 123 F. Supp. 894, 1954 U.S. Dist. LEXIS 3111, 1954 Trade Cas. (CCH) 67,826 (E.D.N.Y. 1954).

Opinion

GALSTON, District Judge.

The action by plaintiff, a manufacturer of pharmaceutical drugs, is to enjoin the defendant, a wholesale drug company, from advertising and selling the plaintiff’s drug products at prices below those established in accordance with the plaintiff’s wholesale fair trade contracts entered into pursuant to the Feld-Crawford Fair Trade Act of New York, § [895]*895369-a et seq., General Business Law, McK.Unconsol.Laws, c. 20.

The defendant has moved to dismiss the action and for summary judgment. The plaintiff in turn has moved for summary judgment, and in the alternative for a temporary injunction. Both sides have submitted affidavits in support of their respective contentions. Defendant has also submitted the deposition of Vincent A. Burgher, vice-president of the plaintiff, in support of its motion. Both motions will be disposed of in this opinion.

The action was instituted in the Supreme Court of the State of New York, Kings County. On the petition of defendant it was removed to this court on the ground of diversity of citizenship, the plaintiff being a New Jersey corporation, and defendant being a New York corporation having its principal place of business in Brooklyn. Plaintiff’s motion for a preliminary injunction was pending at the time.

In February, 1950, plaintiff negotiated contracts with most of the drug wholesalers in the country, including the defendant, establishing minimum wholesale prices on all of plaintiff’s products except hormones. At the time the wholesalers were also asked to sign a “Wholesale Distributors’ Agreement”. A schedule of prices was forwarded to each wholesaler setting forth minimum prices for each of plaintiff’s products. In addition, this schedule carried the notice that it was not applicable to sales in excess of $50. The wholesale distributors’ agreement referred to provided, among other things, that the wholesale distributor would be allowed a 20% discount from the trade list price established by the plaintiff manufacturer as set forth in this schedule of minimum prices.

During this period plaintiff also sold its products directly to a selected group of retailers for the list price less a discount of 20%. Thus plaintiff sold its products to the wholesalers and directly to those retailers at the same price. However, since plaintiff’s wholesale fair trade contracts did not apply to sales by its wholesale distributors in excess of $50 list price, the wholesalers could grant on such sales any discount they desired in selling to retailers. The affidavit of W. Rutherford James, president of defendant corporation, states:

“Of course, Towns & James did not sell Ciba products for the same price we paid for them. But where a customer wanted to purchase Ciba products in quantities of fifty dollars or more, we were able to sell him at a discount of from ten to fifteen per cent. Because of the service and credit we extend to our customers, they-were willing to buy from us at the discounts we offered rather than order from Ciba at their . full discount of 20% off list price.”

On June 29, 1953 plaintiff announced a change in its sales policy. In a letter to its wholesale distributors, a copy of which is attached to defendant’s motion papers, it announced that on July 1, 1953 it was establishing minimum prices for all of its products. At the same time it solicited new manufacturer-wholesaler fair trade contracts, since the 1950 contracts terminated on June 30, 1953. The June 29th letter was accompanied by a copy of the new fair trade contract, and a revised and complete schedule of minimum wholesaler fair trade prices. It is significant that this new schedule omitted the following statement which appeared in the earlier 1950 schedule:

“Products as set forth in this schedule shall be sold in dozens or fractions thereof, or by the unit in any quantity up to fifty ($50) dollars ‘trade list price’, at a price which shall be not less than the indicated list price thereof.”

The defendant executed the new fair trade contract, effective July 1, 1953, with the plaintiff.

On July 28, 1953 the plaintiff issued a letter to its wholesale distributors which, among other things, stated as follows:

“3. The minimum wholesale sell- . ing price, irrespective of quantity, for your shipments of Ciba special- [896]*896■ ties to- druggists, is the ‘price to retailer’ as set forth in the wholesale price catalogue sheet issued -by Ciba, less a discount of not more than 2%.
“4. For years we have extended to drug retail distributors a service allowance of 20%. On July 1, 1953, this special service compensation to drug retail accounts, including Chains, was reduced to 15 % instead of the former 20%.”

The critical effect of the plaintiff's new sales policy with respect to its wholesale distributors, and to its direct retail accounts, was that the wholesale distributors, although obtaining a 20% discount in purchasing from the plaintiff, were required to sell plaintiff’s products to retailers at the list prices established by the plaintiff, whereas the plaintiff was able to sell its products directly to its retail accounts at the list price less 15%.

Following plaintiff’s institution of its new sales policy, the defendant’s sales of the plaintiff’s products declined. Defendant attributed its difficulties in selling plaintiff’s line of products to the new policy and endeavored to obtain relief from the plaintiff. Its talks with the plaintiff’s officers being unsuccessful, defendant notified plaintiff that it was cancelling its fair trade contract. After the cancellation became effective on February 19, 1954, defendant reverted to its sales policy with respect to plaintiff’s products that had been in effect prior to July 1, 1953. On orders for less than $50 defendant continued to charge full list price, as set forth in plaintiff’s price schedule, but on orders in excess of $50, defendant gave discounts to retailers up to 15% of list price.

Thus the affidavit of W. Rutherford James, president of the defendant corporation, admits the advertising and selling of plaintiff’s trademarked products by defendant at wholesale prices below plaintiff’s fair trade wholesale prices. Defendant contends, however, that plaintiff is not entitled to an injunction, or to any relief under the Fair Trade statute* because plaintiff’s, new policy of selling its products directly to retailers at 15% less than the established wholesale prices constitutes an acquiescence on its part in price cutting of its products, and results in unfair competition with its own wholesale customers.

The facts on this vital issue are not in dispute. The plaintiff readily admits to a policy, instituted in July, 1953, to increase its direct retail accounts up to a maximum of 10,000 retail pharmacies from its then total of some 4,000 accounts. That its efforts in this connection were highly successful is indicated by the fact that the number of direct accounts has been increased from approximately 4,000 to 8,000 accounts.

Plaintiff contends, however, that its policy with respect to sales to wholesalers was arrived at wholly separate and apart from its policy with respect to sales to retailers. It refers to a study of more than a year’s duration, conducted by its market research division and by outside consultants, of the problem of obtaining better distribution by itself at the retail pharmacy level.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Gillette Safety Razor Co. v. Green
167 Misc. 251 (New York Supreme Court, 1938)
General Electric Co. v. R. H. Macy & Co.
199 Misc. 87 (New York Supreme Court, 1951)

Cite This Page — Counsel Stack

Bluebook (online)
123 F. Supp. 894, 1954 U.S. Dist. LEXIS 3111, 1954 Trade Cas. (CCH) 67,826, Counsel Stack Legal Research, https://law.counselstack.com/opinion/ciba-pharmaceutical-products-inc-v-towns-james-inc-nyed-1954.